Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04) — CARMEN-LC04

Non-small Cell Lung Cancer Metastatic Clinical Trial

Official title:
Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Tusamitamab Ravtansine (SAR408701) Used in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Metastatic, Non-squamous, Non Small-cell Lung Cancer (NSQ NSCLC) Patients With CEACAM5-positive Tumors, Previously Treated With Platinum-based Chemotherapy and an Immune Checkpoint Inhibitor

Status Active, not recruiting

Clinical Trial Summary

Primary Objectives: Doublet Cohort Part 1 (safety run-in): To assess the tolerability and to confirm the recommended dose of tusamitamab ravtansine in combination with ramucirumab in the NSQ NSCLC population. Part 2: To assess the antitumor activity of tusamitamab ravtansine in combination with ramucirumab in the NSQ NSCLC population. Triplet cohort To assess the tolerability and to confirm the recommended dose of tusamitamab ravtansine in combination with ramucirumab and pembrolizumab in the NSQ NSCLC population. Secondary Objectives: Doublet Cohort To assess the safety and tolerability of tusamitamab ravtansine in combination with ramucirumab. To assess the durability of the response to treatment with tusamitamab ravtansine in combination with ramucirumab. To assess anti-tumor activity of tusamitamab ravtansine in combination with ramucirumab on progression free survival (PFS) and disease control rate (DCR). To assess the pharmacokinetic (PK) profiles of tusamitamab ravtansine (SAR408701) and ramucirumab when given in combination. To assess the immunogenicity of tusamitamab ravtansine (SAR408701) when given in combination with ramucirumab. Triplet cohort To assess the safety and tolerability of tusamitamab ravtansine in combination with ramucirumab and pembrolizumab To assess the antitumor activity of tusamitamab ravtansine in combination with ramucirumab and pembrolizumab in the NSQ NSCLC population. To assess the immunogenicity of tusamitamab ravtansine when given in combination with ramucirumab and pembrolizumab

Clinical Trial Description

The expected duration of the study intervention for participants may vary, based on progression date ; median expected duration of study per participant is estimated 11 months (up to 1 month for screening, a median of 6 months for treatment, and a median of 4 months for end-of-treatment assessments and safety follow-up visit) ;

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Non-small Cell Lung Cancer Metastatic

Clinical Trial Details

NCT number	NCT04394624
Study type	Interventional
Source	Sanofi
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	August 31, 2020
Completion date	September 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01523340` - A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response
Recruiting	`NCT03956641` - Evolution of the Physical Condition in Treated Cancer Patients	N/A
Active, not recruiting	`NCT02035683` - PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy	N/A
Completed	`NCT01848613` - Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC	Phase 4
Suspended	`NCT01320501` - Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer	Phase 4
Terminated	`NCT01471964` - Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer	Phase 1/Phase 2
Recruiting	`NCT06127940` - K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation	Phase 1
Terminated	`NCT04069936` - Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC	Phase 2
Terminated	`NCT03445000` - ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer	Phase 2
Terminated	`NCT03386929` - Survival Prolongation by Rationale Innovative Genomics	Phase 1/Phase 2
Recruiting	`NCT02922764` - A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer	Phase 1
Terminated	`NCT01574300` - Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network
Active, not recruiting	`NCT04646824` - Almonertinib With Chemotherapy in mEGFR NSCLC	Phase 2
Completed	`NCT01966003` - Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer	Phase 3
Recruiting	`NCT03656094` - Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors	Phase 2
Terminated	`NCT01348126` - Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer	Phase 2/Phase 3
Active, not recruiting	`NCT03469960` - Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr	Phase 3
Recruiting	`NCT05919264` - FOG-001 in Locally Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Completed	`NCT04793815` - Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)	N/A
Terminated	`NCT01380795` - Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas	Early Phase 1